Results 41 to 50 of about 5,707 (185)

Serum FGF-23 and α-Klotho Levels in Prolactinoma and Non-Tumoral Hyperprolactinemia: An Exploratory Cross-Sectional Comparative Study

open access: yesDiagnostics
Background/Objectives: This study aimed to evaluate serum fibroblast growth factor-23 (FGF-23) and α-Klotho levels in patients with prolactinoma and patients with non-tumoral hyperprolactinemia and to explore their discriminatory performance for ...
Abdullah Altuğ   +6 more
doaj   +1 more source

The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

open access: yesTrials, 2021
Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen   +23 more
doaj   +1 more source

Continuous outcome estimation in N‐of‐1 trials for accelerated decision‐making

open access: yesEpilepsia, Volume 67, Issue 5, Page 2254-2269, May 2026.
Abstract Objective N‐of‐1 trials aim to determine the therapeutic effect for a single individual. This individualized approach necessitates collecting multiple data points over time through repeated alternating periods of active treatment and a comparator or control condition.
Victoria Defelippe   +5 more
wiley   +1 more source

A case of giant prolactinoma and pituitary hemorrhage with the late recovery of pituitary function: A case report

open access: yesSAGE Open Medical Case Reports, 2023
Hypogonadotropic hypogonadism is a common finding in patients who are diagnosed with a prolactinoma. It can be accompanied by the presence of other pituitary hormone deficits, including secondary adrenal insufficiency and central hypothyroidism.
Lakshmi P Menon, Dinesh Edem
doaj   +1 more source

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

open access: yesAndrology, Volume 14, Issue 4, Page 1002-1016, May 2026.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret   +5 more
wiley   +1 more source

DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut

open access: yesAdvanced Science, Volume 13, Issue 24, 27 April 2026.
Dopamine receptor D2 (DRD2) deficiency disrupts epithelial barrier integrity in both the gut and pituitary gland, facilitating translocation of gut‐derived Escherichia coli into pituitary tissue. Intratumoral E. coli are phagocytosed by microglia, triggering GSDMD‐dependent pyroptosis and HMGB1 release, which subsequently activates MAPK signaling to ...
Xian‐jun Su   +16 more
wiley   +1 more source

An uncommon cause of osteoporosis

open access: yesJournal of Family Medicine and Primary Care, 2018
Osteoporosis in the younger age group is an important cause of morbidity. Prolactinoma is an uncommon but reversible cause of osteoporosis. The main mechanisms of osteoporosis in prolactinoma are reduced osteoblast activity and hypogonadism. A high index
Rohit Barnabas   +5 more
doaj   +1 more source

Very Long‐Term Follow‐Up of Multidimensional Health‐Related Quality of Life After Endoscopic Endonasal Surgery for Pituitary Adenomas: A Prospective Cohort Study

open access: yesHead &Neck, Volume 48, Issue 4, Page 1088-1096, April 2026.
ABSTRACT Background To evaluate postoperative health‐related quality of life (HRQoL) for pituitary adenoma patients, multidimensional assessment is important. Available data is limited on long‐term follow‐up. Methods Prospectively, 52 nonfunctioning (NFA) and functioning (FA) pituitary adenoma patients were included.
Gonneke E. Joustra   +7 more
wiley   +1 more source

Evaluation of Hyperandrogenemia in Women with Prolactinoma

open access: yesEndocrinology Research and Practice, 2020
Objective: Differential diagnosis of androgen excess disorders revealed the occurrence of hyperprolactinemia. However, an elevated level of prolactin (hyperprolactinemia) is a very infrequent cause of hyperandrogenemia in clinical practice.
Mehmet Çağrı ÜNAL   +3 more
doaj  

Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery –Who Is Referring Them?

open access: yesClinical Endocrinology, Volume 104, Issue 4, Page 352-361, April 2026.
ABSTRACT Objective Patients living with pituitary neuroendocrine tumours (PitNETs) present with a spectrum of clinical manifestations and often follow a circuitous route to diagnosis, resulting in diagnostic delays. The objective of this study is to identify and report the various sources of referrals for patients who underwent pituitary resection for ...
Doua S. Ahmed   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy